The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 20 April 2026•Updated 20 April 2026•

1 min read

CelLBxHealth Partners with Royal Marsden for Innovative Lung Cancer Study

Key Facts

1CelLBxHealth announced a research collaboration with The Royal Marsden NHS Foundation Trust to study a novel blood-based testing approach.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to include the 8% share price increase to 0.99p and the addition of the company's Frankfurt Stock Exchange ticker.

CelLBxHealth PLC (AIM:CLBX) has announced a strategic research collaboration with The Royal Marsden NHS Foundation Trust to conduct an advanced clinical study on lung cancer. Following the announcement, the company's shares surged by 8% to reach 0.99p. The partnership focuses on circulating tumour cell (CTC) analysis for 200 patients with advanced non-small cell lung cancer (NSCLC) to validate a novel liquid biopsy approach. In addition to its AIM listing, CelLBxHealth shares are traded on the Frankfurt Stock Exchange under the ticker (FRA:DWV). This collaboration with a prestigious institution aims to provide robust clinical data for the company's diagnostic technology. The market reaction underscores the significance of this milestone for the biotech firm's valuation and its commitment to oncology diagnostics.